Evidence map›Paper›PMID 29802524›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2018

Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis.

M Gil-Raga, E Jantus-Lewintre, S Gallach, V Giner-Bosch, A Frangi-Caregnato, M J Safont-Aguilera, J Garde-Noguera, E Zorraquino-Pina, M García-Martínez, C Camps-Herrero

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

M Gil-RagaMedical Oncology Department, Hospital de Requena, av/Casablanca s/n, 46340, Requena (Valencia), Spain. mir_gil@hotmail.com.ORCID http://orcid.org/0000-0002-4508-7395
E Jantus-LewintreMolecular Oncology Laboratory, CIBERONC, Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain.
S GallachMolecular Oncology Laboratory, CIBERONC, Fundación Investigación Hospital General Universitario de Valencia, Valencia, Spain.
V Giner-BoschCentre for Quality and Change Management, Universitat Politècnica de València, Valencia, Spain.
A Frangi-CaregnatoDepartment of Surgery, Hospital de Sagunto, Valencia, Spain.
M J Safont-AguileraMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
J Garde-NogueraMedical Oncology Department, Hospital Arnau de Vilanova, Valencia, Spain.
E Zorraquino-PinaAnatomic Pathology Department, Hospital de Sagunto, Valencia, Spain.
M García-MartínezMedical Oncology Department, Hospital de Sagunto, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO), Valencia, Spain.
C Camps-HerreroMedical Oncology Department, Hospital General Universitario de Valencia, Valencia, Spain.
Hospital General Universitario De Valencia · ESHospital de Sagunto · ESFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESGeneralitat Valenciana · ESHospital Arnau de Vilanova · ESUniversitat de València · ESUniversitat Politècnica de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAfter surgical resection, an ample prognosis variability among stages is observed. Multiple prognostic factors are individually studied and some CRC classifiers have been proposed. Not one have been implemented into clinical practice. METHODS/PATIENTS: We classified 105 patients with resected CRC (stage I-III) into five molecular subtypes using BRAF RESULTS AND

conclusionsRAS and BRAF

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsDNA Mismatch RepairFemaleGenes, rasHumansMaleMiddle AgedMolecular Diagnostic TechniquesMutationNeoplasm StagingPrognosisBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafColorectal cancerMolecular subtypesPrognostic factor

Identifiers

PMID29802524
OpenAlexW2804128620

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.